Bioavailability of MK-1439 Nano Formulations

Phase 1, open-label, single-arm trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity at 72 hours, Area Under the Plasma Concentration-time Curve From Time 0 to Last Time With Quantifiable MK-1439 at 72 hours and 4 more. Started Sep 2015; status: completed.